

Serial No. 09/646,852, filed Sept. 22, 2000  
Docket No. 1103326-0636  
Page 2 of 10

**AMENDMENT TO THE CLAIMS**

**This listing of claims will replace all prior versions, and listings, of claims in the application:**

Claim 1 (currently amended) A delayed release oral pharmaceutical dosage form

comprising a core material coated with a semipermeable membrane, wherein:

the core material comprises an active ingredient selected from the group consisting of omeprazole, an alkaline salt thereof, *S*-omeprazole and an alkaline salt thereof, one or more alkaline additives, one or more swelling agents, and optionally pharmaceutically acceptable excipients;

the membrane consists essentially of a water-insoluble polymer and a modifying agent and is able to disrupt;

and the dosage form is not enteric coated,

**wherein the modifying agent and water insoluble polymer are present in a weight ratio of from 90:10 to 50:50.**

Claim 2 (cancelled)

Claim 3 (previously presented ) The dosage form according to claim 1, wherein the active ingredient is omeprazole.

Claim 4 (previously presented ) The dosage form according to claim 1, wherein the active ingredient is a magnesium salt of omeprazole having a crystallinity of more than 70% as determined by X-ray powder diffraction.

Claim 5 (previously presented ) The dosage form according to claim 1, wherein the active ingredient is a magnesium salt of *S*-omeprazole.

Serial No. 09/646,852, filed Sept. 22, 2000

Docket No. 1103326-0636

Page 3 of 10

Claim 6 (previously presented ) The dosage form according to claim 1, wherein the core material comprises a sugar sphere layered with a suspension or solution of the active ingredient, one or more alkaline additives, one or more swelling agents and optionally pharmaceutically acceptable excipients.

Claim 7 (previously presented ) The dosage form according to claim 1, wherein the dosage form comprises individual pellets of the core material coated with the semipermeable membrane.

Claim 8 (previously presented ) The dosage form according to claim 1, wherein the core material further comprises an osmotic agent.

Claim 9 (previously presented ) The dosage form according to claim 1, wherein the alkaline additive gives a pH of not less than 8.5 when measured in a 2% w/w water solution/dispersion with a pH-measuring electrode.

Claim 10 (previously presented ) The dosage form according to claim 9, wherein the alkaline additive is selected from the group consisting of disodium hydrogen phosphate, trisodium phosphate, arginine and talc.

Claim 11 (previously presented ) The dosage form according to claim 1, wherein the alkaline additive is present in an amount of approximately 5 to 35% by weight of the core material excluding the weight of an optional sugar sphere.

Claim 12 (previously presented ) The dosage form according to claim 1, wherein the alkaline additive is present in an amount of 15 to 35% by weight of the core material excluding the weight of an optional sugar sphere.

Serial No. 09/646,852, filed Sept. 22, 2000

Docket No. 1103326-0636

Page 4 of 10

Claim 13 (previously presented ) The dosage form according to claim 1, wherein the swelling agent is selected from the group consisting of crosslinked polyvinyl pyrrolidone, crosslinked sodium carboxymethylcellulose, sodium starch glycolate and low-substituted hydroxypropyl cellulose (L-HPC).

Claim 14 (previously presented ) The dosage form according to claim 1, wherein the swelling agent is present in an amount of approximately 20 to 60% by weight of the core material excluding the weight of an optional sugar sphere.

Claim 15 (previously presented ) The dosage form according to claim 1, wherein the swelling agent is present in an amount of 30 to 50% by weight of the core material excluding the weight of an optional sugar sphere.

Claim 16 (previously presented ) The dosage form according to claim 1, wherein the modifying agent is talc or fumed silica.

Claim 17 (previously presented ) The dosage form according to claim 1, wherein the water insoluble polymer is selected from the group consisting of ethylcellulose, cellulose acetate, polyvinyl acetate, and ammonio methacrylate copolymer type A and type B.

Claim 18 (previously presented ) The dosage form according to claim 1, wherein the water insoluble polymer is present in an amount of approximately 3-30% by weight of the core material.

Claim 19 (canceled)

Serial No. 09/646,852, filed Sept. 22, 2000

Docket No. 1103326-0636

Page 5 of 10

Claim 20 (previously presented ) A process for the manufacture of a delayed release dosage form as defined in claim 1, comprising forming a core material comprising an active ingredient selected from the group consisting of omeprazole, an alkaline salt thereof, S-omeprazole and an alkaline salt thereof, one or more alkaline additives, one or more swelling agents, and optionally pharmaceutically acceptable excipients, and coating the core material with a semipermeable membrane, wherein the dosage form has no enteric coating.

Claim 21 (canceled)

Claim 22 (canceled)

Claim 23 (currently amended) A method for improving inhibition of gastric acid secretion which comprises administering to a patient in need thereof, a delayed release oral pharmaceutical dosage form according to any one of claims 1, 3-18 or 28 [~~3-19~~].

Claim 24 (currently amended) A method for improving the therapeutic effect in the treatment of gastrointestinal disorders associated with excess acid secretion which comprises administering to a patient in need thereof, a delayed release oral pharmaceutical dosage form according to any one of claims 1, 3-18 or 28 [~~3-19~~].

Claim 25 (currently amended) A delayed release oral dosage form according to any one of claims 1, 3-18 or 28 [~~3-19~~] filled in a capsule.

Claim 26 (currently amended) A delayed release oral dosage form according to any one of claims 1, 3-18 or 28 [~~3-19~~] compressed into a multiple unit tableted dosage form, optionally comprising tablet excipients.

Serial No. 09/646,852, filed Sept. 22, 2000  
Docket No. 1103326-0636  
Page 6 of 10

27. (previously presented) The dosage form according to any one of claims 11-13, wherein the core material further comprises an osmotic agent.
28. (new) The dosage form according to claim 1, wherein the modifying agent and water insoluble polymer are present in a weight ratio of from 80:20 to 60:40.